Counting the days till Zyprexa's patent runs out

The Zyprexa countdown nears its end. As the Indianapolis Star reports, there are only 21 days remaining on the blockbuster antipsychotic's patent, meaning Eli Lilly will soon face copycat rivals to its biggest-selling medication ever. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.